About Amicus Therapeutics, Inc. 
Amicus Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
Company Coordinates 
Company Details
1 Cedarbrook Dr , CRANBURY NJ : 08512-3618
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 64 Schemes (39.47%)
Foreign Institutions
Held by 141 Foreign Institutions (16.73%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. John Crowley
Chairman of the Board and Chief Executive Officer
Mr. Bradley Campbell
President, Chief Operating Officer, Director
Mr. Michael Raab
Lead Independent Director
Ms. Lynn Bleil
Independent Director
Mr. Robert Essner
Independent Director
Mr. Michael Kelly
Independent Director
Ms. Margaret McGlynn
Independent Director
Revenue and Profits:
Net Sales:
169 Million
(Quarterly Results - Sep 2025)
Net Profit:
17 Million
Pharmaceuticals & Biotechnology
USD 4,439 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.59
-5.36%
19.26






